Windward Bio Files for U.S. Initial Public Offering
The Basel-based biotech plans to list on the Nasdaq under the symbol WWB to fund its clinical-stage antibody pipeline.
Updated on Oct. 23, 2026 in Biotech
Live Poll
Is now a good time for individual investors to put money into new biotech stocks?
Basel-based Windward Bio has filed for a U.S. initial public offering, planning to list its shares on the Nasdaq exchange under the ticker symbol WWB. The company is currently developing antibody-based therapeutics for asthma, chronic obstructive pulmonary disease, and inflammatory skin conditions.
Why it matters
This filing signals the public-market entry for a firm focused on targeting specific inflammatory pathways to treat respiratory and skin conditions. The capital raised in the offering will be directed toward funding the continued development of its clinical-stage pipeline.
Windward Bio has secured $365 million in funding from investors including Novo Holdings, which holds a 14.5% pre-IPO stake, and Blue Owl Capital, which holds a 5.9% stake. The specific financial terms of the upcoming public offering remain pending.
The players
Windward Bio
A Basel-based biotechnology firm developing antibody therapies for asthma, chronic obstructive pulmonary disease, and inflammatory skin conditions.
Novo Holdings
An investment firm and holding company that manages the assets of the Novo Nordisk Foundation, holding a 14.5% stake in Windward Bio.
Blue Owl Capital
An alternative asset manager focused on direct lending and GP capital solutions, holding a 5.9% pre-IPO stake in Windward Bio.
The details
The firm develops antibody treatments designed to block thymic stromal lymphopoietin, a cytokine—a small protein involved in cell signaling—that plays a key role in the immune response associated with asthma and inflammatory skin conditions. Its lead drug candidate, WIN378, is being engineered to modulate this specific protein to mitigate inflammatory responses. The company intends to use the IPO proceeds to advance this therapeutic research.
Timeline
October 16, 2026: Windward Bio officially filed for its U.S. initial public offering.
The Tech Race
Windward Bio is entering a crowded landscape of biotechs targeting respiratory inflammation through cytokine modulation. The move to the Nasdaq exchange follows a pattern set by the Nasdaq exchange's biotechnology listing standards for early-stage companies seeking public market access.
The company plans to list under the symbol WWB, though the timing for when shares will be available for public purchase has not been announced. Investors and medical observers should watch for the subsequent S-1 amendments to determine the specific share price and offering size.
The takeaway
Windward Bio is moving to raise capital on the public markets to support its lead candidate, WIN378. Interested parties should watch for the upcoming pricing and availability of the stock on the Nasdaq exchange.
Further reading
For more on the current landscape of clinical-stage therapeutic development, visit Biotech.
Live Poll
Is now a good time for individual investors to put money into new biotech stocks?
